Provided by Tiger Trade Technology Pte. Ltd.

Immunome Inc.

21.51
-0.3800-1.74%
Post-market: 21.860.3500+1.63%19:30 EDT
Volume:1.31M
Turnover:28.42M
Market Cap:2.44B
PE:-8.66
High:22.56
Open:22.15
Low:21.51
Close:21.89
52wk High:30.06
52wk Low:11.25
Shares:113.58M
Float Shares:108.11M
Volume Ratio:0.71
T/O Rate:1.21%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.4851
EPS(LYR):-2.4315
ROE:-64.03%
ROA:-37.78%
PB:4.65
PE(LYR):-8.85

Loading ...

Immunome initiated with a Hold at Stifel

TIPRANKS
·
5 hours ago

Analysts Offer Insights on Healthcare Companies: Kailera Therapeutics, Inc. (KLRA) and Immunome (IMNM)

TIPRANKS
·
Yesterday

Immunome announces IND clearance for IM-1340 in solid tumors

TIPRANKS
·
Yesterday

Immunome Says FDA Clears IND for IM-1340 Solid Tumor ADC

Reuters
·
Yesterday

Immunome, - to Initiate Phase 1 Study of IM-1340 in Q4 2026

THOMSON REUTERS
·
Yesterday

Immunome Announces Ind Clearance for IM-1340, a Potential First-in-Class Antibody-Drug Conjugate for the Treatment of Solid Tumors

THOMSON REUTERS
·
Yesterday

Immunome initiated with a Buy at Alliance Global

TIPRANKS
·
Sep 21

Immunome, Inc. : Alliance Global Partners Initiates Coverage with Buy Rating; Target Price $32

THOMSON REUTERS
·
Sep 21

Analysts Offer Insights on Healthcare Companies: Fortrea Holdings Inc. (FTRE) and Immunome (IMNM)

TIPRANKS
·
Sep 10

Immunome Price Target Maintained with a $40.00/Share by HC Wainwright & Co.

Dow Jones
·
Sep 10

Immunome Grants 86,500 Inducement Stock Options at $27.07 Per Share

Reuters
·
Sep 09

Immunome Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

THOMSON REUTERS
·
Sep 09

Immunome to Present at H.C. Wainwright Global Investment Conference

Reuters
·
Sep 02

Argenx's Myositis Data Strengthen Efgartigimod Outlook, Morgan Stanley Says

MT Newswires Live
·
Aug 18

Immunome (IMNM) Faces A Valuation Test Following Earnings And Shelf Registration

Simply Wall St.
·
Aug 18

argenx’s VYVGART Hytrulo hits Phase 3 myositis goal in high‑need IMNM and DM

TIPRANKS
·
Aug 17

argenx Announces Positive Topline Results from Phase 3 ALKIVIA Trial of Efgartigimod in Autoimmune Myositis

GlobeNewswire
·
Aug 17

Moleculin Biotech Expects Cash Position to Fund Operations into Q1 2027

Reuters
·
Aug 14

Replimune Q1 Net Loss Narrows as Expenses Decline

Reuters
·
Aug 14

Allarity Therapeutics Q2 Loss Narrows as Expenses Fall

Reuters
·
Aug 14